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Purpose: Poor adherence to prescribed medicines is associated with increased rates of
poor outcomes, including hospitalization, serious adverse events, and death, and is also
associated with increased healthcare costs. However, current approaches to evaluation
of medication adherence using real-world electronic health records (EHRs) or claims data
may miss critical opportunities for data capture and fall short in modeling and representing
the full complexity of the healthcare environment. We sought to explore a framework for
understanding and improving data capture for medication adherence in a population-based
intervention in four U.S. counties.
Approach: We posited that application of a data model and a process matrix when
designing data collection for medication adherence would improve identification of
variables and data accessibility, and could support future research on medication-taking
behaviors. We then constructed a use case in which data related to medication adherence
would be leveraged to support improved healthcare quality, clinical outcomes, and
efficiency of healthcare delivery in a population-based intervention for persons with
diabetes. Because EHRs in use at participating sites were deemed incapable of supplying
the needed data, we applied a taxonomic approach to identify and define variables of
interest. We then applied a process matrix methodology, in which we identified key
research goals and chose optimal data domains and their respective data elements, to
instantiate the resulting data model.
Conclusions: Combining a taxonomic approach with a process matrix methodology may
afford significant benefits when designing data collection for clinical and population-based
research in the arena of medication adherence. Such an approach can effectively depict
complex real-world concepts and domains by “mapping” the relationships between
disparate contributors to medication adherence and describing their relative contributions
to the shared goals of improved healthcare quality, outcomes, and cost.
Keywords: medication adherence, data model, process matrix, taxonomy, health behavior, self-management,
secondary use, cardiometabolic
INTRODUCTION
For patients with chronic illnesses such as diabetes mellitus and
cardiovascular disease, poor adherence to prescribed medicines is
associated with increased rates of hospitalization, serious adverse
clinical events, and death (Balkrishnan, 2005; Ho et al., 2006;
Bitton et al., 2013). Preventable cardiometabolic complications
such as retinopathy, myocardial infarction, heart failure, periph-
eral neuropathy, and amputation are on average 50% more likely
to occur in patients who struggle with medication adherence
(Sokol et al., 2005; Tjia et al., 2010; Chen et al., 2013; Egede et al.,
2013). Healthcare costs associated with poor adherence range
from $100 billion to $300 billion annually (Sokol et al., 2005;
National Council on Patient Information and Education, 2007;
Bowry et al., 2011), contributing significantly to the projected
20% of U.S. gross domestic product to be spent on healthcare by
2020 (Leape et al., 2009).
Despite more than 4 decades of educational, behavioral, and
communication-based interventions to improve adherence, a
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majority of patients are non-adherent to one or more pre-
scribed medicines (Sabate, 2003; Fischer et al., 2010; Davies
et al., 2013; Kyanko et al., 2013). Significant intellectual and
financial investment in research to improve adherence has not
yielded measureable improvements in medication adherence at
the population level, and adherence-related clinical outcomes
have not appreciably changed. This relative lack of progress
may be due in part to issues surrounding the data. The com-
plexity of contributing factors, variability in data definitions,
and inconsistency in terms used in practice and research pre-
vent the successful scaling of interventions from controlled
research settings to real-world populations (Heisler et al., 2010;
Pladevall et al., 2010; Bosworth et al., 2011). Measurement
and data capture from the many entities that contribute to
management of adherence over time, including patients, care-
givers, providers, communities, and health systems, are inac-
cessible or absent (Sanfelix-Gimeno et al., 2013). The purpose
of this article is to describe medication adherence data capture
in a population-based intervention, the Southeastern Diabetes
Initiative (SEDI), which aims to improve healthcare quality, out-
comes, and costs for patients with diabetes mellitus. Based on
our experience in this use case, we posit that developing a
data model and using a process matrix to redesign data col-
lection for medication adherence will improve variable identi-
fication, data access, and future research on medication-taking
behaviors.
APPROACH
USE CASE: THE SOUTHEASTERN DIABETES INITIATIVE (SEDI)
The Southeastern Diabetes Initiative (SEDI) (http://
innovation.cms.gov/initiatives/Health-Care-Innovation-Awards/
North-Carolina.html) is a population-based intervention
designed to address healthcare quality, outcomes, and costs
for patients with diabetes. Using community and clinic-based
clinical teams in four counties in the southeastern United States
(Durham and Cabarrus Counties in North Carolina, Mingo
County in West Virginia, and Quitman County in Mississippi)
we aim to: (1) improve healthcare delivery for individual and
population-level diabetes management; (2) improve outcomes
and quality of life for diagnosed and undiagnosed adults with
type 2 diabetes; and (3) reduce overall healthcare costs for
populations with type 2 diabetes by reducing hospital and
emergency department admissions, improving access through
non-physician providers and technology-enabled consultations,
and providing interventions focused on medication management
and adherence.
USE CASE PROBLEM STATEMENT
Identifying variables for medication adherence is critical to
achieving improvements in quality, outcomes, and costs in SEDI.
Because lack of adherence among diabetes patients is associated
with costly hospitalizations, serious adverse clinical events, and
death (Sokol et al., 2005; Tjia et al., 2010; Chen et al., 2013;
Egede et al., 2013), identifying measurable indicators of medica-
tion adherence and management of medications over time was
an important step in evaluating the work of the clinical team to
improve the quality of healthcare delivery.
At project initiation, we faced the challenge of developing
data collection to record behaviors and interventions associ-
ated with medications. We assumed that the existing electronic
health record (EHR) systems used by our clinical teams would
be adequate to collect information associated with medications
and interventions within the project. However, while develop-
ing our data requirements, we realized that existing EHR data
collection did not capture the granularity necessary for analy-
sis. We therefore designed an independent data collection system
that complemented EHR data collection for each of the four
participating counties.
In the following sections, we discuss our rationale for this
decision and our experience designing data collection for the
intervention.
REQUIREMENTS ANALYSIS
We analyzed data requirements for each of the pre-specified
indicators of medication adherence and management of adher-
ence. These included documentation of variables associated with
the steps in medication reconciliation, shared goal setting, and
planning for management of medications between consulta-
tion intervals. Measures for each of these data requirements
were selected from observable, objective data sources, as well as
from patient-reported, subjective measures such as the Morisky
Medication Adherence Survey (MMAS) (Morisky et al., 2008).
Each data requirement was selected and designated for a mea-
surement frequency that correlated with meaningful intervention
time points. Measures such as the MMAS, Patient Activation
Measure (PAM-13), health literacy assessment (REALM-SF), and
self-care skills assessment for managing medications will be col-
lected at baseline and at follow-up at intervals of 6 months. In
each of the four counties participating in SEDI, these variables
were not available in the EHR. We determined that any effort to
incorporate these forms of data capture into existing EHR systems
would be costly and not feasible within the project timelines.
DEVELOPMENT WORK
A multidisciplinary working team met regularly for 5 months
to develop the data collection design for a stand-alone elec-
tronic data capture system to be used in conjunction with
existing EHR systems. The team comprised clinical providers
(physicians, nurses, nutritionists, licensed clinical social workers,
and community health educators), data analysts, and program-
mers. Consensus was sought for parsimonious variable selec-
tion that would achieve the goal of high-quality, accessible, and
robust measures for medication adherence. After the design was
reviewed by clinical teams in all four counties, it was finalized in
February 2013.
We encountered many decision points during these meetings
that proved important to variable selection and affected project
development. The decisions centered on trade-offs between
choosing highly robust variables (e.g., accuracy, validity and pre-
dictive value of the data elements) and choosing variables that
were feasible to obtain (data availability, accessibility, consis-
tency, completeness, clarity, and the timeliness of data capture)
(Figure 1). Often, the most robust measures were not collected at
the SEDI sites as part of usual care and therefore were not reflected
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FIGURE 1 | Data properties for medication adherence data elements.
in the EHR. This led to feasibility challenges, including the
cost and time commitment required to complete some patient-
reported outcome (PRO) surveys. In addition, many interven-
tions and strategies used to support medication adherence take
place in outpatient settings governed bymultiple regulatory agen-
cies, leading to inconsistent definition of terms and selection of
measures.
To apply consistent decision-making criteria, a list of data
selection and developmental decision points was compiled and
used as a process matrix. We applied judgments within the pro-
cess matrix to make decisions about data quality, access, and the
feasibility of data collection processes for medication adherence
(Table 1A). We then kept a similar list of decision points and
judgments for variable selection and data documentation issues
that would ultimately affect the analysis plan (Table 1B). The
criteria were applied to variable or measure for medication adher-
ence across each of the patient care interactions. Most decision
points were resolved using the clinical, regulatory, data analytics,
and research expertise offered by group members. Because of the
unique multidisciplinary composition of our group, we were able
to engage in constructive discussions that resulted in redirection
of data element selection and lessons learned.
APPLICATION TO CLINICAL INTERVENTION AND CASE STUDY
In the following scenario, we present a hypothetical case study
to provide context for the decisions made regarding data capture
in the SEDI project. This case highlights common patient con-
cerns, provider quandaries regarding medication management,
and caregiver and health system opportunities to support patients
in the daily work of taking medication-taking. The case also high-
lights important opportunities for data capture, many of which
go unrecognized and unfulfilled—resulting in missed chances
to garner fact-based feedback for all participants in the process
of care.
John Doe is a 62-year-old male with uncontrolled type 2 dia-
betes, hypertension, and hyperlipidemia. His medication regimen
includesmetformin 1000mg twice daily, insulin glargine (Lantus)
20 units via subcutaneous injection at night, lisinopril 20mg
daily, and atorvastatin (Lipitor) 40mg daily (Table 2). John Doe
lives alone in an apartment, is currently uninsured, and does not
have personal transportation.
John Doe and a family member were present during his initial
home visit. Mr. Doe reported adherence to his medication reg-
imen. During inspection of pill bottles, both the lisinopril and
atorvastatin bottles were found to have been refilled within the
past month and the appropriate number of pills were left in the
bottle. However, the bottle of metformin had too many pills left
in the bottle and the box of insulin pens sitting on the kitchen
table had expired. The patient stated that his daughter was able to
help him with the cost of the medications for this month, but also
anticipated that he would be unable to pay for the next month’s
supply because his daughter is only present for a short visit.
On further questioning, the patient reported frequently for-
getting to take his metformin at night. He stated he is less likely to
forget his insulin because he kept the box of insulin on the kitchen
table to remind him to take it. While demonstrating insulin
administration, the patient injected insulin into his abdomen but
removed the pen early.
The provider recommended prescribing extended-release met-
formin for once-daily dosing to increase adherence (Table 3). The
community health worker was asked to help the patient submit
a Medicaid application and to help him use public transporta-
tion to obtain medications. The patient was educated regarding
insulin storage, insulin administration, and reviewing insulin
expiration dates.
As illustrated in this use case, adherence to oral medica-
tion can be assessed using pill bottle fill dates, pill counts and
devices such as MEMs caps. However, assessing adherence to
an injectable drug such as insulin poses unique challenges. In
the example above, delivering a dose of insulin requires knowl-
edge of injection technique, and withdrawing the needle prior
to finishing injection can result in delivery of less than a full
dose of medication. Additionally, injecting into areas of lipohy-
pertrophy (areas of fibrosis or lipid tissue deposits) can lead to
less absorption of the insulin. Alternating sites of injection from
areas of slower absorption, such as the thigh, to areas of quicker
absorption, such as the upper arm or abdomen, can lead to vari-
ations in insulin bioavailability. Some insulin regimens require
multiple shots per day that must be taken at certain times with
regard to meals. Insulin expiration dates and storage are addi-
tional variables that are difficult to assess outside of the patient’s
home.
In this clinical case, although prescribed medications were
obtained and initiated, the implementation and management
of the medications was insufficient without considerable sup-
port from family caregivers, providers, and community-based
resources. Data capture for the variables reflecting management
of adherence was also found to be insufficient.
GAP ANALYSIS AND SPECIFICATION OF ADHERENCE TAXONOMY
CONSTRUCTS
Our data collection design related to medication adherence relied
heavily on the combined expertise of the team rather than exist-
ing sources. We found that although some measures were well-
defined, such as the MMAS, we lacked definitive sources and
exact data element specifications to define all variables within
our project, especially to support appropriate measures relat-
ing to medication adherence and leading to robust analyses of
the intervention. We relied on the adherence taxonomy (Vrijens
et al., 2012) for a critical conceptual basis. This taxonomy com-
prises two overarching constructs: Adherence to Medications and
Management of Adherence.
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Table 1A | Process matrix: data collection considerations for medication adherence variable selection.
Data of Data element Feasibility score Robustness score
interest considerations (n/7) (n/5)
Duration of data collection Longitudinal, but with specific focused hypothesis
Longitudinal registry for specific disease
Longitudinal registry, all conditions
 na
Scope of medications of
interest
Study drug only- investigational agent
Specific class of medication only
All prescribed medications
“PRN” or “take as needed” meds
“OTC” or “over the counter” meds
Add vitamins, supplements
na

na
na
na
na
 (prescribed
drugs only)
Data source-medications of
interest
Patient reported drug names
Verification by pill bottles
Computerized physician order entry
Pharmacy records of fills
Pharmacy claims (e.g., Medicaid)




Poor accuracy
Dosing specificity Timing (time of day)
Frequency (x/day, weekly, other)
Dose (mg, tablet, cc)
Taken as directed—with food/without
Route (by mouth, subcutaneous, etc)




Poor accuracy
Measure of prescription fill
rate
Patient reports filling medication
Pharmacy reports fill information
Claims data reports
Add stops and restarts



na



Mode of adherence
measure
Patient reported
Provider observed clinical judgment
Pill bottle counts
Pharmacy refills
DOT (e.g. HIV/TB)
Serum drug level
Pill chips
Bottle lid opens (MEMS cap)

na
na
na
na
na
na
Poor accuracy
Level of data required Binary (adherent/ not adherent)
80% or 100% threshold
Categorical (< 20; 21–80%; > 80%)
Likert scale (1–5)

na
na



The World Health Organization (WHO) has defined
medication adherence as “the extent to which a person’s
medication-taking behavior corresponds with the prescribed
therapeutic regimen” (Sabate, 2003). Yet for researchers attempt-
ing to measure and evaluate these behaviors in relation to clinical
outcomes, this broad definition entails a conundrum of choices
and decisions regarding variable selection, with each option
potentially varying widely across studies. As a result of this
variability, the ability to standardize data elements in an EHR,
case report form, or data warehouse is lost and opportunities to
scale interventions or generalize study findings across settings
and populations are sacrificed. The taxonomy for medication
adherence creates fresh possibilities for both research and prac-
tice (Vrijens et al., 2012). Developed in a series of international
consensus panels hosted by the European Society for Patient
Adherence, Compliance and Persistence (ESPACOMP), the
taxonomy was defined and validated using an established Delphi
technique carried out by the Ascertaining Barriers to Compliance
(ABC) Project from 2009 to 2012. The methodological processes
of these combined efforts have been well described (Vrijens
et al., 2012) and have resulted in international consensus and
validation of terms that define two overarching constructs of
medication adherence: Adherence to Medication and Management
of Adherence (Table 4).
Importantly, this taxonomy distinguishes between the work
associated with taking the prescribed medication (Adherence to
Medication) and the work that supportsmanagement of themedi-
cation (Management of Adherence). The former refers to initiating
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Table 1B | Process matrix: considerations for analysis limitations for medication adherence data.
Data of interest Data options present Limitation Solution
in the dataset present selected
Generalizability One cohort/one condition
More than one cohort/one condition
Multiple conditions
Multiple locations, one system
Multiple health systems
Y/N [name item]
Longitudinal assessment intervals One-time measure only
Planned intervals of assessment (e.g. every 6 months)
Regular + unscheduled contacts
Irregular intervals (e.g. every patient contact; no planned)
Medication data element
codification
Free text with later use of text mining
Free text with later formal medical coding processes
Combinations of free text/codification
Codification at time of data entry (FDB, other schemes)
Medication management support
variables:
codification
Diffuse message/educated (importance of taking drug)
Condition-specific message (diabetes drugs)
Agent-specific education/message (HIV drugs)
Provider consultations (recommend insulin adjustments)
Address physical barriers (transport, cost)
Address social barriers (patient perception)
Data collection timing and mode Prospective (case report form) vs. retrospective
Secondary dataset—electronic or chart abstraction
Direct data collection (real-time data collection/entry)
Hybrid approach in combining both secondary and direct
data capture
Analysis plan for medication
adherence patterns
Intention to treat analysis approach
Patient is on drug on <date>
Measure patient-time-on-drug as being intervals between
report dates (do not assess stops/restarts)
Full-grain detail of stops/restarts
Intended analysis objectives for
outcomes
Drug categories only (HTN, diabetes)
Trends for reduction in dose/frequencies
Trends in adherence/compliance
Observational bias Case controls?
Moving to randomization scheme?
Adding other sources?
Combining active and passive data collection?
Modifying source of observational data collection (EHR
modifies source systems at Duke)
Data incompleteness Accept less power in analyses
Imputation
Increase number of patients
For active data collection, implement processes for
incomplete data alerts
For active data collection, increase efforts to “backfill” data
(site queries, manual chart abstraction)
the medication, persisting in taking the medicine over time, and
discontinuing the medicine at the appropriate time. The latter
encompasses prescribing accurately, facilitating accessibility, and
ensuring the understanding of instructions for administration.
The need to establish these two distinct areas that both con-
tribute to a shared goal is at the heart of achieving the goals
of improved quality, clinical outcomes, and costs. For this rea-
son, we propose that applying this taxonomy to identify EHR
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Table 2 | Example patient data for SEDI MEDICATION LOG data collection.
Drug name Indication Dose Unit Frequency Route Is patient judged to be taking medication
as directed at least 80% of the time?
MEDICATION DATA COLLECTION FOR SEDI PARTICIPANT JOHN DOE ON JANUARY 15, 2013
METFORMIN Type 2 diabetes 1000 MG twice a day By mouth (PO) ©Yes
 No
© Unable to assess
LIPITOR High LDL cholesterol 40 MG Once per day By mouth (PO)  Yes
© No
© Unable to assess
LISINOPRIL High Blood Pressure 20 MG Once per day By mouth (PO)  Yes
© No
© Unable to assess
INSULIN, Lantus Type 2 diabetes 20 Units Once daily Subcutaneous
injection
 Yes
© No
© Unable to assess
variables would advance research in this field and improve data
collection.
DATA DOMAINS, ELEMENTS, AND DEFINITIONS FOR ADHERENCE TO
MEDICATION
The taxonomic construct Adherence to Medication comprises four
domains: initiation, implementation, discontinuation, and persis-
tence. Their distinct representative data elements providemultiple
options for measuring, assessing, and evaluating each distinct
domain.
Table 5A shows data elements within each of the four domains
of Adherence to Medication. Data elements are measureable
components of variables, such as “medication name,” “dose,” “fre-
quency of administration,” and “duration” of prescribed medica-
tion dosing. The definition of a discrete data element is constant,
but the availability of data elements that represent a variable of
interest in a given study context may vary. For example, to mea-
sure and evaluate the variable “medication adherence” in a clinical
efficacy trial, the required data elements might include “medi-
cation name” (i.e., the specific study drug), “dose,” “frequency
of administration,” and “duration of dosing interval (time until
prescribed titration to next dosing interval).”
For the domain initiation, defined as the time at which
the first dose of a medication is taken, commonly used data
elements include “prescribing date” or “prescription fill date.”
Each has unique limitations in terms of accessibility, reliabil-
ity, and validity. For instance, prescription fill date offers an
accessible surrogate for initiation, but its reliability and validity
with regard to actual initiation of medication-taking are lim-
ited. Other, more sensitive data elements in this domain include
MEMS electronic cap removal time stamps, blister pack doc-
umentation, or self-report; each has its respective advantages
and limitations. However, an organizational framework or data
model can formalize a repository of data elements and stan-
dard data definitions for each element and provide a framework
for critical thinking to determine the most robust and accessible
data elements for a given research question in a given study
context.
In contrast, some research questions require less granularity
in data element definition. To measure and evaluate “medication
adherence” as an indicator of quality care in a CMS healthcare
redesign evaluation, selected data elements need only reflect the
guideline-based class of drugs (e.g., beta blocker), as opposed to a
specific medication within that class, such as labetalol. The med-
ication need not be further specified or defined by generic versus
brand name, and the dose, route, and frequency of doses per day
may not be important data elements to capture in this context.
In each of these examples, the discrete data elements required
to achieve a valid, reliable measure of medication adherence
are different. But in each case the need to select one or more
representative data elements from each key domain remains a
critical step in strengthening the study design. By considering
the context in which information will be used, investigators
and practitioners can make informed decisions regarding what
data elements are needed to offer support and feedback or to
draw a conclusion about medication adherence. The formal-
ized data model provides a map for prospectively considering
data element selection instead of relying on a post-hoc, arbi-
trary approach for determining which data elements might be
accessible and available for use. By using a taxonomy-based
data model to assess study design and data element availability,
researchers will be able to prospectively estimate lack of access
and account for this before the analysis and evaluation phases of
a project.
DATA DOMAINS, ELEMENTS, AND DEFINITIONS FOR MANAGEMENT
OF ADHERENCE
The taxonomy described in Vrijens et al. (2012) does not spec-
ify data domains for Management of Adherence, as it does for
Adherence to Medications. Management of Adherence as a unique
taxonomical component is defined as “the process of monitoring
and supporting patients’ adherence to medication by health care
Frontiers in Pharmacology | Pharmaceutical Medicine and Outcomes Research November 2013 | Volume 4 | Article 139 | 6
Granger et al. Adherence indicators in population science
Ta
b
le
3
|E
xa
m
p
le
p
at
ie
n
t
d
at
a
fo
r
A
C
T
IO
N
P
LA
N
d
at
a
co
lle
ct
io
n
.
In
te
rv
en
ti
o
n
d
es
cr
ip
ti
o
n
In
te
rv
en
ti
o
n
p
ri
m
ar
y
fo
cu
s
In
te
rv
en
ti
o
n
p
ri
m
ar
y
ty
p
e
In
te
rv
en
ti
o
n
b
eg
in
d
at
e
In
te
rv
en
ti
o
n
cl
o
su
re
d
at
e
In
te
rv
en
ti
o
n
su
cc
es
s
O
p
ti
o
n
al
in
te
rv
en
ti
o
n
co
m
m
en
ts
A
C
T
IO
N
P
LA
N
FO
R
S
E
D
IP
A
R
T
IC
IP
A
N
T
JO
H
N
D
O
E
O
N
JA
N
15
,2
01
3,
G
E
N
E
R
A
T
E
D
T
H
R
O
U
G
H
D
IS
C
U
S
S
IO
N
B
E
TW
E
E
N
M
R
.D
O
E
,
M
R
.D
O
E
’S
D
A
U
G
H
T
E
R
,A
N
D
S
E
D
IC
LI
N
IC
A
L
T
E
A
M
R
ec
om
m
en
d
M
et
fo
rm
in
do
se
ad
ju
st
m
en
t
to
P
C
P

Pr
ov
id
er
©
Pa
tie
nt
©
Fa
m
ily
m
em
be
r/
ca
re
gi
ve
r

M
ed
ic
at
io
n
©
B
eh
av
io
r
©
R
ef
er
ra
lt
o
m
ed
ic
al
re
so
ur
ce
©
R
ef
er
ra
lt
o
no
n-
m
ed
ic
al
re
so
ur
ce
1/
15
/2
01
3
1/
18
/2
01
3

H
ig
h
©
M
od
er
at
e
©
Lo
w
D
r.
S
m
ith
fr
om
cl
in
ic
al
te
am
co
nt
ac
te
d
M
r.
D
oe
’s
P
C
P,
D
r.
Jo
ne
s,
w
ho
co
nc
ur
re
d
w
ith
M
et
fo
rm
in
do
se
ad
ju
st
m
en
t,
an
d
su
bm
itt
ed
eP
re
sc
rip
tio
n
to
M
r.
D
oe
’s
ph
ar
m
ac
y
A
dd
re
ss
co
st
of
M
et
fo
rm
in
©
Pr
ov
id
er

Pa
tie
nt
©
Fa
m
ily
m
em
be
r/
ca
re
gi
ve
r
©
M
ed
ic
at
io
n
©
B
eh
av
io
r
©
R
ef
er
ra
lt
o
m
ed
ic
al
re
so
ur
ce

R
ef
er
ra
lt
o
no
n-
m
ed
ic
al
re
so
ur
ce
1/
15
/2
01
3
©
H
ig
h
©
M
od
er
at
e
©
Lo
w
M
r.
D
oe
’s
ap
pl
ic
at
io
n
fo
r
M
ed
ic
ai
d
se
rv
ic
es
ha
s
no
t
be
en
su
bm
itt
ed
.R
ef
er
re
d
M
r.
D
oe
to
C
om
m
un
ity
H
ea
lth
W
or
ke
r
fo
r
as
si
st
an
ce
in
fil
in
g
ap
pl
ic
at
io
n
A
dd
re
ss
tr
an
sp
or
ta
tio
n
ba
rr
ie
r
fo
r
ph
ar
m
ac
y
pi
ck
-u
ps
©
Pr
ov
id
er
©
Pa
tie
nt

Fa
m
ily
m
em
be
r/
ca
re
gi
ve
r
©
M
ed
ic
at
io
n
©
B
eh
av
io
r
©
R
ef
er
ra
lt
o
m
ed
ic
al
re
so
ur
ce

R
ef
er
ra
lt
o
no
n-
m
ed
ic
al
re
so
ur
ce
1/
15
/2
01
3
©
H
ig
h
©
M
od
er
at
e
©
Lo
w
M
r.
D
oe
’s
da
ug
ht
er
ha
s
ha
d
tr
ou
bl
e
pi
ck
in
g
up
M
r.
D
oe
’s
pr
es
cr
ip
tio
ns
at
ph
ar
m
ac
y.
R
ef
er
re
d
M
r.
D
oe
’s
da
ug
ht
er
to
C
om
m
un
ity
H
ea
lth
W
or
ke
r
fo
r
as
si
st
an
ce
in
bu
s
ro
ut
e
sc
he
du
lin
g.
A
dd
re
ss
dr
ug
ex
pe
ct
at
io
ns
(s
id
e
ef
fe
ct
s;
sy
m
pt
om
re
sp
on
se
)
©
Pr
ov
id
er

Pa
tie
nt

Fa
m
ily
m
em
be
r/
ca
re
gi
ve
r

M
ed
ic
at
io
n

B
eh
av
io
r
©
R
ef
er
ra
lt
o
m
ed
ic
al
re
so
ur
ce
©
R
ef
er
ra
lt
o
no
n-
m
ed
ic
al
re
so
ur
ce

H
ig
h
©
M
od
er
at
e
©
Lo
w
A
dd
re
ss
an
y
ne
ed
ed
su
pp
or
ts
fo
r
dr
ug
ad
m
in
is
tr
at
io
n
©
Pr
ov
id
er

Pa
tie
nt

Fa
m
ily
m
em
be
r/
ca
re
gi
ve
r

M
ed
ic
at
io
n

B
eh
av
io
r
©
R
ef
er
ra
lt
o
m
ed
ic
al
re
so
ur
ce
©
R
ef
er
ra
lt
o
no
n-
m
ed
ic
al
re
so
ur
ce

H
ig
h
©
M
od
er
at
e
©
Lo
w
A
dd
re
ss
pl
an
fo
r
dr
ug
ac
co
m
m
od
at
io
n
or
ad
ap
ta
tio
n
of
da
ily
lif
e
©
Pr
ov
id
er

Pa
tie
nt

Fa
m
ily
m
em
be
r/
ca
re
gi
ve
r

M
ed
ic
at
io
n

B
eh
av
io
r
©
R
ef
er
ra
lt
o
m
ed
ic
al
re
so
ur
ce
©
R
ef
er
ra
lt
o
no
n-
m
ed
ic
al
re
so
ur
ce

H
ig
h
©
M
od
er
at
e
©
Lo
w
www.frontiersin.org November 2013 | Volume 4 | Article 139 | 7
Granger et al. Adherence indicators in population science
Table 4 | Summary of the taxonomy and definitions of medication adherence∗
Taxonomy Definition
Adherence to medications The process by which patients take their medications as prescribed, composed of initiation, implementation and
discontinuation.
Initiation occurs when the patient takes the first dose of a prescribed medication.
Discontinuation occurs when the patient stops taking the prescribed medication, for whatever reason(s).
Implementation is the extent to which a patient’s actual dosing corresponds to the prescribed dosing regimen, from
initiation until the last dose.
Persistence is the length of time between initiation and the last dose, which immediately precedes discontinuation.
Management of adherence The process of monitoring and supporting patients’ adherence to medications by health care systems, providers,
patients, and their social networks.
*From Vrijens et al. (2012).
Table 5A | Taxonomy domains and element definitions: adherence to medication.
Data domains Data elements Data capture metric
Initiation Pharmacy data for fill date—Medication possession ratio (MPR)
Pharmacy data for refills—Proportion of days covered (PDC)
Medication electronic monitoring systems (MEMS caps)
Directly observed therapy (DOT)—hospital dispensed at discharge
Patient-reported start date—follow up call questions
MPR; PDC; MEMS
DOT; F/U call data point
Implementation Medication electronic monitoring systems (MEMS caps)
Patient-reported adherence-Morisky medication adherence scale (MMAS survey)
MEMS
MMAS
Discontinuation Pharmacy data for refill frequency—prescription stop date
Patient-reported stop date
MPR; PDC
F/U call data point
Persistence Self-report; MPR; PDC TEACHBACK; MMAS; MPR; DEDUCE
Table 5B | Taxonomy domains and element definitions: management of medication.
Data domains Data elements Data capture metric
Self-management Attend appointments: A1c measurement and lipid levels
Self-monitor: blood glucose, blood pressure, weight (med-related fluid balance)
Use reminder strategies: pillbox, logs, technology-based reminder alarms, watches
Pharmacy reported prescription fill/refill rates
Self-reported surveys of self-care:
DSCI; DSME; SCHFI; MMAS
MPR; PDC
Provider support Listen; explain; support behaviors; communicate feedback (specifically regarding
labs/logs/reported symptoms or side effects)
Client Centered Care Questionnaire (CCCQ)
HCAHPS-item #
CTM #1-3
CAHPS
HL item 1-4
PCMH items x-z
CCCQ
Caregiver support Emotional; tangible; informational; companionship Surveys/self-report/interviews
Health system support CMS 5-star rating
HCAHPS – Coleman CTM-3
CAHPS – PCMH & HL items;
Behavioral Economics-based med adherence incentives
HEDIS metrics / fill / refill rates
Surveys (Likert scale)
Social network support On-line/live group participation; frequency of network engagement Interview/text fields
Network participation counts
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FIGURE 2 | Proposed data model.
systems, providers, patients and their social networks” (Vrijens
et al., 2012, p. 697). It can therefore be characterized by the
domains of self-management and support for self-management,
including support provided by healthcare systems, health policy,
communities, providers, caregivers, and patients’ social networks.
In addition, “shared goal setting” as it relates to medications is an
implicit domain within the construct from both a provider and
patient-centered perspective. Examples of the data domains and
possible data elements representing each are shown in Table 5B.
These data domains and their respective data elements must
be further defined, integrated, and validated if application of
the taxonomy is to yield meaningful, patient-centered measures
and describe feasible roles for families, providers, and health
systems.
METHODOLOGY FOR INSTANTIATING THE DATA MODEL THROUGH A
PROCESS MATRIX
Using the taxonomy as a guide to specify desirable variables
within each of the two major constructs, we defined a process
for application and implementation. Initial steps for applying
the taxonomy include: (1) defining data domains, or groups of
related data elements for two taxonomic constructs: Adherence
to Medication and Management of Adherence; (2) identifying
data elements, including definitions and attributes, within each
data domain; (3) aligning data elements with international
standards; and (4) instantiating the taxonomy into use (i.e.,
applying and evaluating the performance of data domains and
data elements) into multiple contexts, including EHR systems
and research data collection. An overview of the development
and instantiation processes are shown in Figure 2. Using well-
defined structured data improves research processes such as
variable identification, data capture, measurement methodology,
and the subsequent reliability and validity of the data obtained.
Well-defined data are associated with improved analytic out-
comes, because the greater precision and accuracy yields greater
relational specificity among identified variables in a statistical
model.
Just as the taxonomy facilitates identification of data domains
and data elements for medication adherence-related sciences, the
process matrix facilitates selection of domains and elements for
specific research questions. Selection of the optimal data element
FIGURE 3 | Actor diagram.
is often determined by the context in which the study is con-
ducted and by the feasibility of obtaining a metric in a setting
or patient population. For each research question, the process
matrix shown in Table 1 facilitates critical thinking about options
for data element access and selection. These options are based on
the established study endpoints and further defined by the con-
text of the study sample and setting. For example: study purpose
and scope; study design, sample, and setting; timing of measure-
ment; procedures; and study analysis plan all describe functional
components of the research question and can be used to identify
data domains and systematically select the most appropriate data
elements.
To demonstrate how the medication adherence data model
facilitates research from the perspective of key stakeholders,
patients, providers, healthcare systems, and industry, the follow-
ing section describes use of the process matrix to complement the
stakeholder scenarios presented in Figure 3.
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APPLICATION OF THE PROCESS MATRIX METHODOLOGY FOR
RESEARCH
The first step for using the process matrix is to clarify key research
goals. What is the dependent variable or primary outcome of
interest? Is adherence the primary outcome (dependent vari-
able) or a contributor (independent variable) to a more relevant
primary outcome, such as serious clinical events or mortality?
Choosing domains and data elements requires thoughtful eval-
uation of the project objectives and data accessibility. The value
of adherence lies in evidence that taking the medication yields a
valuable clinical outcome.
For example: taking statins decreases serious clinical events
and mortality in patients with diabetes (Fallis et al., 2013). Yet the
extent to which medication-taking actually occurs is < 50%, and
this poor adherence contributes to the current failure to improve
these important clinical outcomes. The data model therefore
identifies possible standardized data options for studying medica-
tion adherence. The process matrix is designed to optimize data
element selection for medication adherence as a moderator, or
intermediate dependent variable, for clinical events and mortality
as key clinical outcomes in the defined population (e.g., patients
with type 2 diabetes). To accomplish the first step in the process
matrix, identify the endpoint or dependent variable of interest
and consider the role of medication-taking in relation to that
primary endpoint.
For another example, consider the question: “What is the
relationship between adherence to metformin (as measured by
hemoglobin A1c < 6) and incidence of myocardial infarction in
patients with type 2 diabetes?” The following key questions arise:
How much adherence? How much of the time? To all medica-
tions or just some? Adherence by what measure? Answering these
questions and using a process matrix to evaluate available data
elements can yield greater specificity in the actual terms and vari-
ables used in the research question. A more measurable research
question, if longer term clinical events are not available, may be:
“What is the relationship between adherence tometformin or oral
agents and levels of hemoglobin A1c at 6, 12, and 24 months in
patients with type 2 diabetes?”
In this example, each of these questions can be answered
by the data elements and definitions in the taxonomic con-
struct Adherence to Medications. However, if the objective is to
improve adherence, and the research question is “what factors
influence/improve medication adherence?” then the second con-
struct (Management of Adherence) becomes a central source for
considering and selecting data elements.
The second step in using the process matrix after choosing
the primary endpoint is to choose the domains and respective
data elements. Data elements must be specified or selected for
each domain in a research question. Therefore, as shown in
Figure 3, data elements must be selected for independent vari-
ables as well as the primary dependent variable in the study. An
endpoint or dependent variable (e.g., stroke) will require selec-
tion of several independent variables, one of which will be blood
pressure. However, there are multiple data element options for
blood pressure: systolic blood pressure, diastolic blood pressure,
mean arterial blood pressure, and others. The process matrix
can facilitate selection of specific, accessible data elements with
standardized definitions, making study findings more general-
izable and valuable to health systems, patients, providers, and
researchers.
Choosing data elements and data definitions is a context-
driven selection process. “Data element” refers to the most
atomistic level of the data being described. Rather than “blood
pressure,” data elements should be specified as described above
(i.e., as systolic, diastolic, or mean arterial pressure). The infor-
mation implicit in the label or name of each data element defines
that element. For example, if the data element were “prescribed
medication frequency,” permissible values for that data element
might be: 1 ×/daily, 2×/daily, every other day, or “as needed.”
Likewise, “medication name” should be specified as brand name,
generic name, or simply “drug class.”
The context of the variable is determined by the mode of data
collection. For example, medication frequency could refer to pre-
scribed frequency or actual frequency of intake, and could be
measured using self-report, MEMS cap data, or an EHR value.
Selecting the data definition from among these options depends
on the setting and context of the data element within the domain
and the larger context of the study.
The logistics of data collection within a study design depend
upon the context in which data will be collected. For exam-
ple, data collection may be active (such as prospectively asking
patients to bring pill bottles to a clinic visit and counting the
pills) or passive (such as within the context of continuous or sec-
ondary use that utilizes previously collected data in an EHR or
enterprise data warehouse). In the passive context, recognizing
the domain as well as the individual data elements becomes even
more important. Patient-reported medication lists and doses and
dosing frequency often differ from medications prescribed and
documented in computerized physician order entry (CPOE) sys-
tems in EHRs; yet each of these contexts may have similar data
elements.
Research on medication adherence in the context of
population-based interventions designed to improve quality, out-
comes, and cost requires careful specification of data elements
across all domains. The process matrix can be used to consider
variable access and availability in passive EHR data systems. It
can also be helpful in prioritizing active data collection efforts
to obtain the most important incomplete data elements for key
research questions.
DISCUSSION
In the course of our initial attempts to devise a frame-
work for capturing medication adherence data in the setting
of a population-based intervention, we realized existing EHR
data sources in the four participating counties were insuffi-
cient for research aimed at supporting the aims of improved
quality, clinical outcomes, and costs in patients with dia-
betes. To identify key indicators of medication adherence and
management of adherence, we applied taxonomic constructs
(and their accompanying data domains, elements, and def-
initions) and a process matrix methodology to ensure data
accessibility. Using this structured approach to identify pre-
specified variables amplified the wide gaps in EHR data cap-
ture for the data elements reflecting both Medication Adherence
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and provider and health system support for Management of
Adherence.
Lack of data connectivity and reciprocity across settings of
care delivery has been identified as a key factor in poor data
capture (Kush et al., 2007; Abernethy et al., 2010). Behavioral
strategies to support medication-taking in this population were
broadly implemented through clinics, community venues, and
patient home visits, yet EHRs in each of the four county sites
lacked designated fields for documenting participation in these
interventions. This oversight rendered impossible the task ofmea-
suring and collecting feedback regarding the impact of these
care processes, and key stakeholders lacked data to support
effective communication regarding participation in adherence
interventions. For example, the Stanford Chronic Disease Self-
Management Program (CDSMP) (Lorig et al., 2001), which was
offered in short sessions once a week for 6 weeks in community
settings such as churches, senior living facilities, and community
education centers, was not represented in data capture. Patient
participation in these programs was difficult to ascertain from
EHRs.
Because data capture was absent or, at best, available
only in the isolated setting in which the program was
offered, progress toward targeted adherence goals was diffi-
cult to measure. Actual patient data could not be included
in communications between patients and providers to sup-
port program participation or the need for redirection. Thus,
the quality of care improvement initiatives failed to provide
key metrics that could affect clinical endpoints, and exist-
ing sources of data such as EHRs fail to capture impor-
tant measures of research quality data for adherence-related
variables.
A second major barrier to data capture was the inability
to effectively use the national drug code (NDC) information
(U.S. Food and Drug Administration, 2013) from the various
EHR and claims datasets across each county system for adher-
ence purposes. Though NDC codification provides a unique
10-digit drug identifier for each FDA-approved medication, the
3-segment numeric indicator of the vendor, product specifica-
tion (strength, dose, and formulation of the drug), and trade
package are not standardized. Only the first segment is a fixed
identifier from the FDA, while the second and third segments
vary by company and product. As a result, although NDC cod-
ification is intended to greatly improve data quality through
coded, standardized identifiers, the stage at which the codes are
implemented in the EHR system is critical. For example, all
health systems in the four-county project use medication data
collection that starts with patient-reported, free-text medication
names. Codification and drug mapping occur later, after the
data are collected. Although this is logical for “usual care,” it
is less precise and requires more processing. When NDC codes
are captured at point of dispensation or provider ordering in
the EHR, the data quality gap is closed and drug adherence
tracking to the community pharmacy level is possible. This level
of sophistication in use of NDC codes is not yet widely avail-
able, and this lack contributes to the gap in data quality and
accessibility.
THE OPPORTUNITY TO ADVANCE THE SCIENCE OF ADHERENCE USING
THE TAXONOMY
The application of the adherence taxonomy for research provides
a rich opportunity for identifying and selecting standardized
measures and metrics for a wide variety of research questions
and study designs. The value lies in specifying and standardiz-
ing definitions, measures and metrics for each of the overarching
constructs of the taxonomy. This step lays the foundation for
subsequent work to integrate these data element definitions and
standards across electronic data platforms that include pharma-
cies, EHRs, and insurance claims databases (Raebel et al., 2013)
as well as electronic data platforms of associated care delivery
devices such as telephone and home technology devices. Other
settings where patients receive support for management of adher-
ence, such as health departments, dialysis clinics, retail stores, and
community-based healthcare education settings must also be able
to share standardized data definitions and measures if we are to
advance the science of management of adherence as a data-driven
construct.
In our four-county samples, the variation in data reflecting
medication management was staggering. For example, in edu-
cation plans, care plans, and methods of evaluation chosen for
each of these patient-provider consultations, what was measured
and documented about medication-taking varied substantially.
Likewise, the specification of role-responsibilities for support-
ing the management of adherence across participant groups
including patients, caregivers, providers, health systems, and
community-based resource groups, was highly variable and not
accessible for analysis in existing electronic platforms. Our find-
ings suggest opportunities to specify standard measures for man-
agement of adherence to reframemedication-taking as a behavior,
one in which all actors—patients, caregivers, providers, health
systems, and communities—play a measurable role. Doing so
changes the culture of management of adherence by recognizing
needed shifts in responsibilities for the work of adherence, and by
reflecting those shifts in the data that are captured for evaluation.
Applying the taxonomy through use of electronic data capture
systems has the added potential to create consistent, standard-
ized measures of self-management and support strategies across
population of patients, providing the opportunity for useful com-
parative effectiveness studies on management of adherence in the
future.
BENEFITS TO PATIENTS, PROVIDERS, HEALTHCARE SYSTEMS, AND
INDUSTRY
The need exists to conceptually map data domains and elements,
as well as data sources embedded in care delivery processes that
contribute to medication adherence on a larger scale. Such a map
would lend structure and definition to the data capture required
for innovative study designs and would incorporate the com-
plex relationships between individuals, providers, health system
and environmental factors that contribute to medication adher-
ence. In addition, the map would allow for more systematic
approaches to study broad-scale adherence interventions and to
evaluate the relationship of improved adherence to clinical events
and mortality across patient populations.
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A conceptual model has rarely held tangible value for patients,
clinicians or the financially driven business of healthcare systems
or the pharmaceutical industry. Yet in this case the model pro-
vides a schematic diagram to guide movement in both practice
and research to identify measureable indicators of management
of adherence. By measuring key contributing factors from each
of the players in the adherence game, data-driven solutions for
improvement may be more readily identified. The data model
allows measurement of life choices, behaviors, resources and sup-
port structures to becomemore clearly visible. Integrating process
models that reflect management of medications across everyday
life, healthcare delivery and access with data models that reflect
the data sources and data elements at each process step enables
the conceptual data model to effectively map opportunities for
improving through visibility of meaningful, real-time data (Payne
et al., 2009).
Such a data model would benefit patients and providers by
informing care delivery in meaningful way; it accounts not only
for the patient and the pills, but also for the complexity of the
broader landscape of social determinants of health, including
family, community, access to information technology, and health
system support. Such a data model may provide a roadmap to
guide the transition of adherence evaluation from the controlled
world of clinical trials to the messiness of population-based set-
tings that capture “big data” by using EHRs, claims data, or
community-level studies that evaluate thousands of people in
real time, as in the case of the SEDI project. This concept was
aptly illustrated by Kent (1978), who observed that in the real
world,”. . . highways are not painted red, rivers don’t have county
lines running down the middle, and you can’t see contour lines
on a mountain. The task of the data modeler is to create order
out of chaos without excessively distorting the truth.” As we
have observed in designing data collection for the SEDI project,
current approaches to population-based evaluation of adherence
fall short of the truth by missing critical opportunities for data
capture. As a result, the opportunity is lost to effectively har-
ness data reflecting key principles of the behavioral economics of
medication-taking.
CONCLUSIONS
We propose that the approach developed for operationalizing the
taxonomic domains for Management of Adherence in the SEDI
project will allow more effective analysis and will more accurately
depict the messiness of the real world by mapping the relation-
ships among disparate contributors to medication adherence and
describing their relative contributions to the goals of achieving
improved quality, clinical outcomes, and costs. This formative
work suggests that opportunities exist to further develop and test
a broad data model for adherence—one that depicts a detailed
roadmap of avenues for variable selection related to adherence
and management of adherence.
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